designing and development of a dna vaccine based on structural proteins of hepatitis c virus

Authors

roghayeh teimourpour

antimicrobial resistance research center, mashhad university of medical sciences, mashhad, iran amineh sadat tajani

pharmacy school, mashhad university of medical sciences, mashhad, iran vahid reza askari

pharmacy school, mashhad university of medical sciences, mashhad, iran sina rostami

the influenza centre, department of clinical science, university of bergen, n-5021 bergen, norway zahra meshkat

abstract

background: hepatitis c virus (hcv) infection is one of the most prevalent infectious diseases responsible for high morbidity and mortality worldwide. therefore, designing new and effective therapeutics is of great importance. the aim of the current study was to construct a dna vaccine containing structural proteins of hcv and evaluation of its expression in a eukaryotic system. methods: structural proteins of hcv (core, e1, and e2) were isolated and amplified from jfh strain of hcv genotype 2a using pcr method. the pcr products were cloned into pcdna3.1 (+) vector and finally were confirmed by restriction enzyme analysis and sequencing. the eukaryotic expression of the vector was confirmed by rt-pcr. results: recombinant vector containing 2241bp fragment of hcv structural genes was constructed.the desired plasmid was sequenced and corresponded to 100% identity with the submitted sequences in genbank. rt-pcr results indicated that the recombinant plasmid could be expressed efficiently in the eukaryotic expression system. conclusion: successful cloning of structural viral genes in pcdna3.1 (+) vector and their expression in a eukaryotic expression system facilitates the development of new dna vaccines against hcv. a dna vaccine encoding core-e1-e2 antigens was designed. the desired expression vector can be used for further attempts in the development of vaccines.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Designing and Development of a DNA Vaccine Based On Structural Proteins of Hepatitis C Virus

Background: Hepatitis C virus (HCV) infection is one of the most prevalent infectious diseases responsible for high morbidity and mortality worldwide. Therefore, designing new and effective therapeutics is of great importance. The aim of the current study was to construct a DNA vaccine containing structural proteins of HCV and evaluation of its expression in a eukaryot...

full text

Designing and Development of a DNA Vaccine Based On Structural Proteins of Hepatitis C Virus.

BACKGROUND Hepatitis C virus (HCV) infection is one of the most prevalent infectious diseases responsible for high morbidity and mortality worldwide. Therefore, designing new and effective therapeutics is of great importance. The aim of the current study was to construct a DNA vaccine containing structural proteins of HCV and evaluation of its expression in a eukaryotic system. METHODS Struct...

full text

Hepatitis C Virus and Vaccine Development

The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical u...

full text

Immunogenicity Evaluation of a DNA Vaccine Expressing the Hepatitis C Virus Non-Structural Protein 2 Gene in C57BL/6 Mice

Backgrounds: Most of the hepatitis C virus (HCV) infections elicit poor immune responses and 75% to 85% of cases become chronic therefore, the development of an effective vaccine against HCV is of paramount importance. In this study, we aimed to evaluate co-administration of HCV non-Structural Protein 2 and IL-12 DNA vaccines in C57BL/6 mice. Methods: A plasmid encoding full-length HCV NS2 prot...

full text

hepatitis c virus and vaccine development

the prevalence of hepatitis c virus (hcv) is approximately 3% around the world. this virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. the effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. hence, generating new vaccines or drugs is an obligation. however, there is no vaccine available for clinical u...

full text

Enhanced Immune Responses of a Hepatitis C Virus core DNA Vaccine by co-Inoculating Interleukin-12 Expressing Vector in Mice

Background: Hepatitis C (HCV) is a worldwide problem without an effective vaccine with more than 170 million chronically infected people worldwide. DNA vaccines expressing antigenic portions of the virus with adjutants have recently been developed as a novel vaccination technology. Objectives: In the present study, a DNA vaccine expressing HCV core protein was developed with IL12 as a genetic a...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of pathology

جلد ۱۱، شماره ۳، صفحات ۲۲۲-۲۳۰

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023